M
Moderna, Inc. (MRNA)
NMS – Real Time Price. Currency in USD
53.27
+0.39 (0.74%)
At close: May 12, 2026, 4:00 PM EDT
53.44
+0.17 (0.32%)
Pre-market: May 13, 2026, 4:55 AM EDT
Find any stock by ticker or company name

NMS – Real Time Price. Currency in USD
53.27
+0.39 (0.74%)
At close: May 12, 2026, 4:00 PM EDT
53.44
+0.17 (0.32%)
Pre-market: May 13, 2026, 4:55 AM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 2.41 | 6.05 | 10 | |
| Quick ratio | 2.35 | 5.63 | 10 | |
| Debt to Equity | 0.18 | 0.30 | 9.0 | |
| Debt to Assets | 0.11 | 1.04 | 8.0 | |
| Interest coverage | -81.65 | -16.91 | 1.0 | |
| Weighted average score | 7.6 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 19.11B | 6.84B | 3.24B | 1.94B | 2.23B |
| Gross Profit | 13.35B | 1.53B | 1.58B | 861M | 257M |
| Operating Income | 9.27B | -4.25B | -3.94B | -3.07B | -3.41B |
| Net Income | 8.36B | -4.71B | -3.56B | -2.82B | -3.19B |
| EBITDA | 9.61B | -3.63B | -3.76B | -2.86B | -3.18B |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | -30.78 | 3.31 | 2.5 |
| Next quarter | -9.5 | -131.33 | 1.0 |
| Current year | 7.27 | -17.2 | 3.0 |
| Next year | 19.85 | 44.38 | 9.5 |
| Weighted average score | 4.0 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | -42.62 | -62.58 | -61.13 | -177.66 | 1.0 |
| Y/Y | 260.19 | -38.3 | -34.91 | 40.03 | 5.5 |
| 3y average | -52.26 | -37.04 | -38.24 | -46.79 | 1.0 |
| 5y average | 407.78 | 318.14 | 279.95 | 74.9 | 10 |
| Weighted average score | 4.4 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | Medium | 7.0 |
| Intangible assets | Wide | 9.0 |
| Switching costs | Medium | 7.0 |
| Network effect | Medium | 5.0 |
| Economies of scale | Medium | 7.0 |
| Weighted average score | 7.0 | |
Company's cash reserves $1.9B significantly exceed its total debt $1.3B, ensuring strong financial flexibility
Total current assets $5.8B exceed Total current liabilities $2.4B, highlighting excellent liquidity
Debt-to-equity ratio (0.2) is well below the industry average (0.3), showcasing prudent financial management
Interest coverage ratio (-81.6x) is dangerously low, suggesting debt repayment risks
Negative free cash flow -$692.0M limits the company's ability to reinvest or pay down debt